Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS PEDIATRIC (CM): Erenumab in Children and Adolescents With Chronic Migraine
jRCT2080225076Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of erenumab in chronic migraine (3 arms), sponsored by Amgen. Started Feb 2020; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2080225076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225076.